Revenue (Quarterly)

Revenue: The sum of all revenue fields included for a company's operating activities.

IGC Pharma, Inc. (IGC) had Revenue of $0.32M for the most recently reported fiscal quarter, ending 2026-03-31.

Quarterly Annual

Figures for fiscal quarter ending 2026-03-31

Income Statement Financials
Revenue	$0.32M
Net Income	$-2.40M
Cost of Goods Sold	$0.26M
Gross Profit	$0.06M
Operating Expenses	$2.77M
Operating Income	$-2.46M
Non-Operating Income/Expense	$0.06M
Pre-Tax Income	$-2.40M
Normalized Pre-Tax Income	$-2.40M
Income after Taxes	$-2.40M
Income from Continuous Operations	$-2.40M
Consolidated Net Income/Loss	$-2.40M
Normalized Income after Taxes	$-2.40M
EBIT	$-2.46M
EBITDA	$-2.46M
Weighted-Average Shares Outstanding (Basic)	98.16M
Weighted-Average Shares Outstanding (Diluted)	98.16M
Earnings per Share (EPS) (Basic)	$-0.02
Earnings per Share (EPS) (Diluted)	$-0.02
Balance Sheet Financials
Current Assets	$1.15M
Property, Plant, and Equipment	$2.10M
Long-Term Assets	$8.04M
Total Assets	$9.19M
Current Liabilities	$2.87M
Long-Term Debt	$0.19M
Long-Term Liabilities	$0.19M
Total Liabilities	$3.06M
Common Equity	$6.12M
Tangible Shareholders Equity	$0.85M
Shareholders Equity	$6.12M
Common Shares Outstanding	98.80M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-1.22M
Cash Flow from Investing Activities	$-0.17M
Cash Flow from Financial Activities	$0.71M
Beginning Cash	$0.90M
End Cash	$0.21M
Increase/Decrease in Cash	$-0.69M
Stock-Based Compensation	$1.01M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	0.40
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.03
Debt to Equity Ratio	0.15
Gross Margin	17.35%
Operating Margin	-775.39%
EBIT Margin	-775.39%
EBITDA Margin	--
Pre-Tax Profit Margin	-757.73%
Profit Margin	-757.73%
Free Cash Flow	$-1.22M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.03
Inventory Turnover	0.41
Receiveable Turnover	8.57
Days Sales in Receivables	10.50
Return on Equity	-39.24%
Return on Tangible Equity	-281.59%
Return on Assets	-26.15%
Return on Investments	-38.05%
Book Value Per Share	$0.06
Free Cash Flow per Share	$-0.01
Operating Cash Flow per Share	$-0.01

Data from Zacks Investment Research, Inc.